PharmaResearch Launches Renewed ‘Rejoderm Ato Cream MD’

PharmaResearch, a specialist in regenerative medicine, has announced the renewed launch of its medical-grade moisturizer, ‘Rejoderm Ato Cream MD,’ specifically designed for medical institutions.

The Rejoderm MD product line includes both ‘Rejoderm Ato Cream MD’ and ‘Rejoderm Ato Lotion MD.’ The renewed ‘Rejoderm Ato Cream MD’ serves as a second-tier medical device designed to form a physical barrier over damaged skin areas, such as burns or severely dry skin. It contains PharmaResearch's unique patented ingredient, c-PDRN (hydrolyzed DNA), and is primarily utilized in dermatology and pediatrics.

This renewal aimed to maintain the moisturizing efficacy of the original product while improving the sensory experience based on user feedback. PharmaResearch has focused on reducing the distinctive scent of the ingredients to enhance the practical usability experienced during application. The company states that they have elevated the product’s overall quality by considering both functional characteristics and ease of use.

A PharmaResearch representative explained, “This renewal reflects our careful consideration of actual user feedback while maintaining the unique advantages of Rejoderm MD Cream.” They added, “We will continue to monitor not only the functionality of our products but also the experiences that users have, enhancing the quality and competitiveness of Rejoderm MD products over time.”